| Literature DB >> 30288386 |
Zahra Sarrafan-Chaharsoughi1, Masoud Reza Manaviat2, Nasim Namiranian3, Pouria Yazdian-Anari4, Masoud Rahmanian5.
Abstract
BACKGROUND: Type 2 diabetes mellitus (T2DM) is one of the most important leading causes of disability, premature mortality and Diabetic Retinopathy (DR) that is one of the diabetes-related complications in diabetic patients and the most common cause of vision loss in diabetic patients. The aim of the study was to evaluate the association between DR and body mass index (BMI) in those patients with T2DM.Entities:
Keywords: Body mass index; Diabetic retinopathy; Type 2 diabetes mellitus
Year: 2018 PMID: 30288386 PMCID: PMC6154516 DOI: 10.1007/s40200-018-0339-5
Source DB: PubMed Journal: J Diabetes Metab Disord ISSN: 2251-6581
Basic characteristics of type II diabetic patients (푛 = 518) divided into five groups according to diabetic retinopathy status
| Variables | Group1 ( | Group2 ( | Group3 ( | Group4 (n = 30) | Group5 ( | P value* |
|---|---|---|---|---|---|---|
| Age, y | 59.35 ± 10.46 | 62.66 ± 9.45 | 63.98 ± 10.06 | 63.8 ± 8.47 | 63.27 ± 8.86 | 0.001 |
| Male, n (%) | 118(59.9) | 9(4.6) | 23(11.7) | 11(5.6) | 36(18.3) | 0.39 |
| Diabetes Duration, n (%) | 8.85 ± 6.17 | 15.96 ± 7.14 | 16.96 ± 7.39 | 13.73 ± 6.07 | 18.28 ± 8.03 | 0.001 |
| <5 years | 116 (92.8) | 0 (0) | 2 (1.6) | 2 (1.6) | 5 (4) | |
| 5–10 years | 56 (67.5) | 7 (8.4) | 7(8.4) | 6(7.2) | 7 (8.4) | 0.001 |
| ≥10 years | 119 (41.9) | 44 (15.5) | 22 (7.7) | 70 (24.6) | ||
| Insulin use, n (%) | 64(39.3) | 14(8.6) | 23(14.1) | 16(9.8) | 46(28.2) | 0.001 |
| BMI, (kg/m2) | 27.97 ± 4.47 | 28.05 ± 4.29 | 27.92 ± 3.24 | 27.7 ± 4.02 | 27.68 ± 4.75 | 0.99 |
| Patient weight, (kg) | 73.98 ± 13.94 | 72.6 ± 11.67 | 72.92 ± 9.76 | 7.12 ± 10.13 | 72.35 ± 13.63 | 0.72 |
| Patient height, (cm) | 162.06 ± 10.14 | 159.64 ± 7.78 | 161.56 ± 9.3 | 160.3 ± 7.07 | 161.78 ± 9.8 | 0.62 |
| 129.4 ± 16.56 | 123.43 ± 14.67 | 135.29 ± 16.79 | 136.55 ± 17.98 | 139.43 ± 22.12 | 0.001 | |
| Diastolic blood pressure, (mmHg) | 77.15 ± 7.82 | 78.29 ± 8.99 | 77.12 ± 7.1 | 75 ± 6.68 | 78.72 ± 9.03 | 0.25 |
| Systemic hypertension, n (%) | 131(58.5) | 16(7.1) | 23(10.3) | 11(5.6) | 36(18.3) | 0.11 |
Data presented are means (SD) or number (%), as appropriate
Group 1: no retinopathy, Group 2: mild non-proliferative diabetic retinopathy; Group 3: moderate non-proliferative diabetic retinopathy, Group 4: severe non-proliferative diabetic retinopathy Group 5: proliferative diabetic retinopathy
*P-value for linear trend in mean characteristics across quartiles based on 2 or ANOVA. Bold denotes a significant trend
Fig. 1Prevalence of DR among 518 T2DM patients
Fig. 2Prevalence of any stage of DR for the Diabetes Duration
Fig. 3BMI of T2DM (푛 = 518) divided into five groups according to DR status
Comparisons between patients with NDR and DR, patients with NPDR and PDR
| Variables | NDR (n = 306) | NPDR ( | PDR ( | p-value* |
|---|---|---|---|---|
| Age, y | 59.35 ± 10.46 | 63.5 ± 9.47 | 63.27 ± 8.86 | 0.001 |
| Male, n (%) | 118 (59.9) | 43 (21.8) | 36 (18.3) | 0.46 |
| BMI, (kg/m2) | 27.97 ± 4.47 | 27.9 ± 3.74 | 27.68 ± 4.75 | 0.88 |
| Patient weight (kg) | 73.98 ± 13.94 | 72.38 ± 10.39 | 72.35 ± 13.63 | 0.42 |
| Patient height (cm) | 162.06 ± 10.14 | 160.68 ± 8.34 | 161.78 ± 9.8 | 0.42 |
| Systemic hypertension, n (%)htn | 131(58.5) | 53(23.7) | 40(17.9) | 0.04 |
| Systolic blood pressure, (mmHg) | 129.4 ± 16.56 | 134.74 ± 16.43 | 139.43 ± 22.12 | 0.001 |
| Diastolic blood pressure, (mmHg) | 77.15 ± 7.82 | 76.94 ± 7.65 | 78.72 ± 9.03 | 0.27 |
| HbA1c level (%) | 8.1 ± 1.47 | 8.88 ± 1.59 | 8.91 ± 1.64 | 0.001 |
| Poor glycemic control (%)**hba1c > 7 | 64(83.1) | 8(10.4) | 5(6.5) | 0.001 |
| Previous MI, n (%) | 43(47.3) | 26(28.6) | 22(24.2) | 0.002 |
| Previous stroke, n (%) | 10(45.5) | 7(31.8) | 2(22.7) | 0.28 |
| Total cholesterol, (mmol/L) | 182.49 ± 42.58 | 180.8 ± 41.94 | 191.62 ± 73.24 | 0.42 |
| LDL cholesterol, (mmol/L) | 106.03 ± 36.8 | 106.3 ± 31.63 | 101.48 ± 40.39 | 0.78 |
| HDL cholesterol, (mmol/L) | 44.32 ± 12.24 | 42.89 ± 14.18 | 42.49 ± 10.42 | 0.61 |
| Diabetes duration, n (%) | 8.85 ± 6.17 | 15.84 ± 7.07 | 18.28 ± 8.03 | 0.001 |
| <5 years | 116 (92.8) | 4 (3.2) | 5 (4) | |
| 5–10 years | 56 (67.5) | 20 (24.1) | 7 (8.4) | 0.001 |
| ≥10 years | 119 (41.9) | 95 (33.5) | 70 (24.6) |
Data presented are means (SD) or number (%), as appropriate
NDR, no retinopathy, NPDR, non-proliferative diabetic retinopathy; Group 3: proliferative diabetic retinopathy
*P-value for linear trend in mean characteristics across quartiles based on 2 or ANOVA. Bold denotes a significant trend
**Poor glycemic control defines as HbA1c up to 7
Metabolic and clinical parameters of type 2 diabetic patients (푛 = 518) divided into five groups according to diabetic retinopathy status
| Variables | Group1 (n = 306) | Group2 (n = 38) | Group3 (n = 58) | Group4 ( | Group5 (n = 86) | P value |
|---|---|---|---|---|---|---|
| HbA1c level, (%)* | 8.1 ± 1.47 | 8.79 ± 1.61 | 8.77 ± 1.5 | 9.21 ± 1.78 | 8.91 ± 1.64 | 0.001 |
| Poor glycemic control, n (%)** | 170(59.6) | 21(7.4) | 34(11.9) | 16(5.6) | 44(15.4) | 0.005 |
| Previous MI, n (%) | 43(47.3) | 8(8.8) | 13(14.3) | 5(5.5) | 22(24.2) | 0.01 |
| Previous stroke, n (%) | 10(4.5) | 3(13.6) | 1(4.5) | 3(13.6) | 5(22.7) | 0.18 |
| Total cholesterol, (mmol/L) | 182.49 ± 42.58 | 188.67 ± 35.43 | 174.08 ± 42.06 | 184.84 ± 48.11 | 191.62 ± 73.24 | 0.53 |
| LDL cholesterol, (mmol/L) | 106.03 ± 36.8 | 102.13 ± 23.55 | 103.19 ± 30.13 | 120.09 ± 43.38 | 101.48 ± 40.39 | 0.65 |
| HDL cholesterol, (mmol/L) | 44.32 ± 12.24 | 45.71 ± 20.54 | 43.24 ± 10.43 | 37.73 ± 8.16 | 42.49 ± 10.42 | 0.44 |
| Triglyceride, (mmol/L)tg | 180.68 ± 102.45 | 181.24 ± 74.91 | 136.44 ± 65.01 | 179.89 ± 72.16 | 228.87 ± 212.77 | 0.02 |
| Microalbuminuria, (mg/g)ma | 19.18 ± 33.74 | 60.11 ± 97.58 | 59.99 ± 88.23 | 68 ± 81.87 | 125.02 ± 145.23 | 0.001 |
Data presented are means (SD) or number (%), as appropriate
Group 1: no retinopathy, Group 2: mild non-proliferative diabetic retinopathy; Group 3: moderate non-proliferative diabetic retinopathy, Group 4: severe non-proliferative diabetic retinopathy Group 5: proliferative diabetic retinopathy
*P-value for linear trend in mean characteristics across quartiles based on 2 or ANOVA. Bold denotes a significant trend
**Poor glycemic control defines as HbA1c up to 7
Multiple logistic regressions of diabetic retinopathy
| Items | B | S.E | Wald | Sig. | OR |
|---|---|---|---|---|---|
| Diabetes duration | 0.15 | 0.03 | 30.49 | 0.001 | 1.17 |
| Insulin therapy | 0.81 | 0.36 | 5.02 | 0.02 | 2.24 |
| Weight | −0.011 | 0.015 | 0.61 | 0.43 | 0.99 |
| SBP | 0.011 | 0.01 | 1.18 | 0.28 | 0.011 |
| MI | 0.16 | 0.42 | 0.14 | 0.71 | 1.17 |
| HbA1c | 0.38 | 0.12 | 9.53 | 0.002 | 1.46 |